COVID-19

iMedRIS Clients Leading Large COVID-19 Studies

Many iMedRIS clients are dedicating all their resources to understanding COVID-19 and contributing to finding a vaccine sooner.

iMedRIS Clients Leading Large COVID-19 Studies

We know that this is a difficult time for all of us as we seek to keep ourselves and our families safe from the effects of COVID-19. We want to applaud those who have put themselves on the front line of this battle to provide care and essential services so that life can still go on.

While we shelter at home, many iMedRIS clients, including UCSF, Duke University, City of Hope and those from State and Federal entities, continue to work tirelessly for COVID-19 research. Their research will contribute toward finding vaccines for pharmacological and therapeutic applications for antibody immunity and clinical trials on various antiviral drugs approved under FDA emergency use authorization (EUA). 

Ethics/ Clinical Management, IRB, IBC and IACUC committees use iRIS (our Integrated Research Information System)  a cloud-based software to efficiently exact regulatory compliance.

Members of these institutions also serve as advisors to the highest levels of government as they seek to make informed decisions on what the best course of action is. We want these institutions to know that we appreciate all of the work they are doing and we are here to support them through the days, weeks and months ahead. It is because of them that we see a light at the end of the tunnel.

We were so pleased to see the articles below of our clients contributing to COVID-19. Check out their stories by clicking on the institutions below.

Scroll to Top

Schedule a Demo

Request for Proposal